Palouse Capital Management Inc. Has $570,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Palouse Capital Management Inc. lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,487 shares of the medical instruments supplier’s stock after selling 61 shares during the quarter. Palouse Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $570,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BDX. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $25,000. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $29,000. REAP Financial Group LLC increased its stake in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares during the last quarter. Picton Mahoney Asset Management increased its stake in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $34,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BDX. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research note on Thursday, May 1st. Piper Sandler lowered shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 1st. Finally, Bank of America lowered shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target on the stock. in a research note on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $219.22.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now directly owns 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,104 shares of company stock valued at $399,675 in the last ninety days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $172.06 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $183.03 and a 200 day simple moving average of $213.07. The company has a market cap of $49.31 billion, a P/E ratio of 28.58, a P/E/G ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the prior year, the firm earned $3.17 EPS. The business’s revenue was up 4.5% on a year-over-year basis. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.